drug discovery bottlenecks
What is it about?
Drug Discovery is shifting focus from the industry to outside partners and in the process creating new bottlenecks, suggesting the need for a more disruptive overhaul. We suggest there needs to be an awareness of what research is going on in the academic screening centers, more collaboration and coordination. These efforts will shift the focus to finding the best researchers to fund and require a rethink of how to reward their collaborative efforts.
Why is it important?
This opinion was later expanded and published by DDT. The emphasis here was using computational approaches to predict safety and efficacy.
The following have contributed to this page: Dr Antony John Williams and Dr Sean Ekins
In partnership with: